NEW YORK, Feb. 7, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on OPGN, PRAH, DGX, and TROV which can be accessed for free by signing up to www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on OpGen Inc. (NASDAQ: OPGN), PRA Health Sciences
Shares in Gaithersburg, Maryland headquartered OpGen Inc. plummeted 8.73%, ending Tuesday's trading session at $2.51. The stock recorded a trading volume of 229,076 shares. The Company's shares are trading 48.95% below their 50-day moving average. Moreover, shares of OpGen, which engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide, have a Relative Strength Index (RSI) of 34.49.
On February 01st, 2018, OpGen announced that it has introduced a Research Use Only Acuitas® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test was developed to detect the most common bacterial causes of cUTI directly from urine (E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, E. faecalis) and isolated colonies. Additionally, the gene panel detects 47 gene targets that convey resistance to antibiotics. Get the full research report on OPGN for free by clicking below at:
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock rose 1.01%, closing the day at $88.29. A total volume of 535,230 shares was traded, which was above their three months average volume of 462,130 shares. The Company's shares have advanced 5.84% in the previous three months and 49.90% over the past year. The stock is trading 12.22% above its 200-day moving average. Additionally, shares of the Company have an RSI of 43.33.
On January 24th, 2018, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', with a target price of $86 per share.
On January 24th, 2018, PRA Health Sciences announced that it will release its Q4 and year-end 2017 results after the market closes on February 21st, 2018. The Company will host a conference call on February 22nd, 2018, at 9:00 a.m. ET to discuss these results. A live audio broadcast will be available under the investor relations section of the Company's website. Access the free research report on PRAH now by signing up at:
On Tuesday, shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 1.66 million shares, which was higher than their three months average volume of 1.15 million shares. The stock ended the day 1.03% higher at $101.13. The Company's shares have advanced 1.22% in the past month, 7.48% in the previous three months, and 9.00% over the past year. The stock is trading above its 50-day moving average by 1.28%. Furthermore, shares of Quest Diagnostics have an RSI of 45.56.
On February 01st, 2018, Quest Diagnostics (DGX) announced that it has completed its previously announced acquisition of Mobile Medical Examination Service (MedXM), a leading national provider of home-based health risk assessments and related services. This acquisition will strengthen DGX's mobile provider capabilities and population health management solutions for health plans, as well as bolster its Extended Care services. Financial terms of the agreement were not disclosed.
On February 02nd, 2018, research firm Credit Suisse resumed its 'Neutral' rating on the Company's stock, with a target price of $107 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on DGX at:
San Diego, California headquartered TrovaGene Inc.'s stock jumped 9.47%, finishing yesterday's session at $0.34. A total volume of 2.48 million shares was traded, which was above their three months average volume of 1.57 million shares. The Company's shares are trading below their 50-day moving average by 10.55%. Additionally, shares of TrovaGene have an RSI of 51.67.
On January 24th, 2018, TrovaGene announced the initiation of its Phase-2 clinical trial, evaluating the combination of PCM-075 and abiraterone acetate (Zytiga® - Johnson & Johnson) in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). The study will enroll 25 patients with mCRPC, who are showing early signs of disease progression while on abiraterone/prednisone therapy and will evaluate the proportion of patients achieving disease control after 12 weeks of study treatment. Aspiring Member, please take a moment to register below for your free research report on TROV at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-research-stocks----opgen-pra-health-sciences-quest-diagnostics-and-trovagene-300594920.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All